The earnings call reflected a strong performance for LivaNova in the second quarter of 2025, with significant revenue growth, successful clinical milestones, and improved financial health. However, supply chain constraints and an increased tax rate were noted as challenges.

Company Guidance

During the LivaNova PLC second quarter 2025 earnings call, the company reported a 10% organic revenue growth compared to the previous year, primarily driven by strong performance in the cardiopulmonary and neuromodulation sectors. Cardiopulmonary segment revenue increased by 13%, reaching $199 million, with heart-lung machines and oxygenators showing low double-digit growth. The epilepsy segment saw a 6% revenue increase, with significant contributions from Europe and the Rest of the World regions. LivaNova raised its full-year 2025 revenue growth guidance to 9% to 10% on an organic basis. The company also highlighted notable clinical achievements, including long-term data from the CORE-VNS study, which showed an 80% median seizure reduction in patients with focal onset seizures. LivaNova is pursuing national Medicare coverage for VNS therapy in treatment-resistant depression, supported by strong data from the RECOVER study. Additionally, the company is progressing with its FDA submission for obstructive sleep apnea treatment. The revised guidance reflects strong first-half performance, updated revenue expectations, and improved operational execution.

Strong Organic Revenue Growth

LivaNova delivered a 10% organic revenue growth year-over-year, driven by momentum in the cardiopulmonary business and solid neuromodulation performance across all regions.

Cardiopulmonary Segment Performance

The cardiopulmonary segment achieved a revenue of $199 million, a 13% increase compared to Q2 2024, with significant contributions from heart-lung machines and oxygenators.

Epilepsy Segment Achievements

Epilepsy revenue increased by 6% compared to the previous year, with notable growth in both U.S. and international markets, and successful transition to the updated SenTiva generator.

Positive Clinical Milestones

Long-term results from the CORE-VNS study showed significant seizure reductions, supporting the effectiveness of VNS therapy in drug-resistant epilepsy.

Debt Reduction and Cash Flow

Total debt decreased to $431 million from $628 million at the end of 2024, and adjusted free cash flow improved to $68 million in the first half of the year.

Guidance Raise for 2025

The company raised its organic growth outlook to between 9% and 10% for 2025, reflecting strong performance and successful business execution.

LivaNova (LIVN) Earnings, Revenues Date & History

The upcoming earnings date is based on a company’s previous reporting, and may be updated when the actual date is announced

Daily Earnings Calendar >

LIVN Earnings History

Report Date	Fiscal Quarter	Forecast / EPS	Last Year's EPS	EPS YoY Change	Slides	Play Transcript
Oct 29, 2025	2025 (Q3)	0.92 / -	0.9	―	―	―
Aug 06, 2025	2025 (Q2)	0.87 / 1.05	0.93	12.90% (+0.12)
May 07, 2025	2025 (Q1)	0.76 / 0.88	0.73	20.55% (+0.15)
Feb 25, 2025	2024 (Q4)	0.80 / 0.81	0.87	-6.90% (-0.06)
Oct 30, 2024	2024 (Q3)	0.72 / 0.90	0.73	23.29% (+0.17)
Jul 31, 2024	2024 (Q2)	0.78 / 0.93	0.78	19.23% (+0.15)
May 01, 2024	2024 (Q1)	0.49 / 0.73	0.43	69.77% (+0.30)
Feb 21, 2024	2023 (Q4)	0.77 / 0.87	0.81	7.41% (+0.06)
Nov 01, 2023	2023 (Q3)	0.64 / 0.73	0.58	25.86% (+0.15)
Jul 26, 2023	2023 (Q2)	0.54 / 0.78	0.53	47.17% (+0.25)

The table shows recent earnings report dates and whether the forecast was beat or missed. See the change in forecast and EPS from the previous year.

Beat

Missed

LIVN Earnings-Related Price Changes

Report Date	Price 1 Day Before	Price 1 Day After	Percentage Change
Aug 06, 2025	$42.61	$47.36	+11.15%
May 07, 2025	$35.16	$43.50	+23.72%
Feb 25, 2025	$49.50	$41.70	-15.76%
Oct 30, 2024	$52.97	$51.34	-3.08%

Earnings announcements can affect a stock’s price. This table shows the stock's price the day before and the day after recent earnings reports, including the percentage change.

FAQ

When does LivaNova PLC (LIVN) report earnings?

LivaNova PLC (LIVN) is schdueled to report earning on Oct 29, 2025, Before Open (Confirmed).

What is LivaNova PLC (LIVN) earnings time?

LivaNova PLC (LIVN) earnings time is at Oct 29, 2025, Before Open (Confirmed).

Where can I see when companies are reporting earnings?

You can see which companies are reporting today on our designated earnings calendar.

What companies are reporting earnings today?

You can see a list of the companies which are reporting today on TipRanks earnings calendar.

What is LIVN EPS forecast?

LIVN EPS forecast for the fiscal quarter 2025 (Q3) is 0.92.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing